(+)-JQ1

Catalog No.S7110

(+)-JQ1 Chemical Structure

Molecular Weight(MW): 456.99

(+)-JQ1 is a BET bromodomain inhibitor, with IC50 of 77 nM/33 nM for BRD4(1/2) in cell-free assays, binding to all bromodomains of the BET family, but not to bromodomains outside the BET family.

Size Price Stock Quantity  
USD 270 In stock
USD 570 In stock

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

7 Customer Reviews

  • The BET protein inhibitor JQ1 reduces c-Myc expression and attenuates primary MCC cell proliferation. A, decreased c-Myc expression in MCC-3 and MCC-5 treated with JQ1 (800 nmol/L) for 72 hours by qRT-PCR and immunoblotting. The mRNA expression of target genes was normalized to that of MRPS2 and a value of 1.0 was assigned to the mRNA expression of target genes in the control group (means+SEM; **, P < 0.01 vs. control); b-actin was used as a loading control for immunoblotting.

    Cancer Res 2014 74(23), 7090-102. (+)-JQ1 purchased from Selleck.

    Immunohistochemical staining of xenograft tumor tissues. Immunohistochemical staining of xenograft tumor tissues with the indicated antibodies. p21-, p27-, p57-, and Ki67 positive cells (brown staining) were quantified at x400 magnification (meansSEM;**, P < 0.01;***, P < 0.001 vs. control); scale bars, 10 um.

    Cancer Res 2014 74(23), 7090-102. (+)-JQ1 purchased from Selleck.

  • (D) Effect of JQ1 on alterations of actin cytoskeleton in VEGF-induced HUVECs. The cells were pretreated with DMSO or JQ1 (100 nM) for 6 h, and stimulated with VEGF (10 ng/mL) for 12 h. F-actin (red) and nuclei (blue) were stained with phalloidin and DAPI, respectively. Representative images from 3 independent experiments.

    Sci Rep, 2016, 6:23770.. (+)-JQ1 purchased from Selleck.

    Sensitivity of BEZ235-resistant cells to JQ-1 using the MTT assay.

    Oncotarget, 2016, 6(7):5134-46.. (+)-JQ1 purchased from Selleck.

  • B. Repressed MCC-3 xenograft tumor growth upon combined treatment with MLN0128 and JQ1. Tumor bearing mice were treated with MLN0128 or vehicle at 1 mg/kg/day by oral gavage and JQ1 or vehicle at 50 mg/kg/day by i.p. injection for a period of 30 days. C. A more effective reduction of MCC-3 xenograft tumor growth in the group treated with combined therapy. Fold-reduction of tumor growth was calculated as average tumor growth of control group divided by average tumor growth of treatment group. Tumor growth was calculated as final average tumor volume minus initial average tumor volume in each group.

    Oncotarget, 2016, 7(6):6576-92.. (+)-JQ1 purchased from Selleck.

    JQ1 induces cell cycle arrest and apoptosis in Cal27 cells. (C) Cal27 cells were treated with JQ1 for 24 h and whole cell lysates were tested by western blot assays for the expression of cleaved-caspase-3. GAPDH was used as a loading control. (D) Apoptosis of Cal27 cells treated with JQ1 at 0 and 0.5 µM JQ1; *P<0.05 vs. control (the DMSO group)

    Oncol Rep, 2016, 36(4):1989-96.. (+)-JQ1 purchased from Selleck.

  • Effect of BET domain family inhibition on AMI damage in cardiomyocytes. (A) LDH and (B) CK-MB activity in the serum. #P<0.01 vs. sham group; @P<0.05 and &P<0.01 vs. AMI group. BET, bromodomain and extra-terminal; AMI, acute myocardial infarction; LDH, lactate dehydrogenase; CK-MB, creatine kinase MB isoenzyme.

    Exp Ther Med, 2015, 10(6):2319-2324.. (+)-JQ1 purchased from Selleck.

Purity & Quality Control

Choose Selective Epigenetic Reader Domain Inhibitors

Click to view more

Notes:

2. For more details, such as half maximal inhibitory concentrations (IC50s) and working concentrations of each inhibitor, please click on the link of the inhibitor of interest.
3. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation.
4. Orange "√" refers to compounds which do inhibitory effects on the related isoform, but without specific value.

Biological Activity

Description (+)-JQ1 is a BET bromodomain inhibitor, with IC50 of 77 nM/33 nM for BRD4(1/2) in cell-free assays, binding to all bromodomains of the BET family, but not to bromodomains outside the BET family.
Features (+)-JQ1 is more effective than (-)-JQ1.
Targets
BRD4 (2) [1]
(Cell-free assay)
BRD4 (1) [1]
(Cell-free assay)
33 nM 77 nM
In vitro

(+)-JQ1 enantiomer binds directly into the Kac binding site of BET bromodomains. (+)-JQ1 (500 nM) binds BRD4 competitively with chromatin resulting in differentiation and growth arrest of NMC cells. (+)-JQ1 (500 nM) attenuates rapid proliferation of NMC 797 and Per403 cell lines as demonstrated by reduced Ki67 staining. (+)-JQ1 (500 nM) potently decreases expression of both BRD4 target genes in NMC 797 cells. (+)-JQ1 inhibits cellular viability with IC50 of 4 nM in NMC 11060 cells. [1] (+)-JQ1 results in robust inhibition of MYC expression in MM cell lines. (+)-JQ1 inhibits proliferating of KMS-34 and LR5 with IC50 of 68 nM and 98 nM, respectively. (+)-JQ1 (500 nM)-treated MM.1S cells results in a pronounced decrease in the proportion of cells in S-phase, with a concomitant increase in cells arrested in G0/G1. (+)-JQ1 (500 nM) results in pronounced cellular senescence by beta-galactosidase staining. (+)-JQ1 (800 nM) exposure leads to a significant reduction in cell viability among the majority of CD138+ patient-derived MM samples tested. [2] (+)-JQ1 inhibits growth of LP-1 cells with GI50 of 98 nM. (+)-JQ1 (625 nM) results in an increase in the percentage of LP-1 cells in G0/G1. (+)-JQ1 (500 nM) suppresses the expression of MYC, BRD4 and CDK9 in LP-1 cells. [3] (+)-JQ1 (1 μM) activates HIV transcription in latently infected Jurkat T cells. (+)-JQ1 (50 μM) stimulates predominantly Tat-dependent HIV transcription in both Jurkat and HeLa cells. (+)-JQ1 (5 μM) induces Brd4 dissociation enables Tat to recruit SEC to HIV promoter and induce Pol II CTD phosphorylation and viral transcription in J-Lat A2 cells. JQ1 enables Tat to increase CDK9 T-loop phosphorylation and partially dissociates P-TEFb from 7SK snRNP in Jurkat T cells. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
K1  M2LwbWNmdGxiVnnhZoltcXS7IFHzd4F6 MnPQNlUxNzVyMD:xNFAxKG6P MnPvNlQwPDhxN{KgbC=> NFHz[odFVVOR MojobY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliaX6gZo91cCCmb4PlMUBidmRidHnt[U0h\GWyZX7k[Y51KG2jbn7ldi=> MlW5NlY4ODd6OEG=
BCPAP MoHUR4VtdCCYaXHibYxqfHliQYPzZZk> MkDCNlUxNzVyMD:xNFAxKG6P NVvhO3hGOjRxNEivO|IhcA>? MWHEUXNQ NYi4fmw6cW6qaXLpeJMh[2WubDD2bYFjcWyrdImgbY4h[m:2aDDkc5NmNSCjbnSgeIlu\S1iZHXw[Y5l\W62IH3hco5meg>? M3PJVlI3PzB5OEix
K1  NV\HWYxNS2WubDDDfYNt\SCDc4PhfS=> MYmyOVAwPTByL{GwNFAhdk1? MmHGO|IhcA>? NULITZlZTE2VTx?= MnPmZZJz\XO2czDj[YxtKGO7Y3zlJIF1KEdyL1exJJBp[XOn MnnNNlY4ODd6OEG=
BCPAP NVvRR3kxS2WubDDDfYNt\SCDc4PhfS=> M1rEflI2OC93MECvNVAxOCCwTR?= Ml7JO|IhcA>? NYLBd2JNTE2VTx?= MnzzZZJz\XO2czDj[YxtKGO7Y3zlJIF1KEdyL1exJJBp[XOn NYjyb45ZOjZ5MEe4PFE>
Hep3B M{PxNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1WyPFAuOTBizszN M3zjOlUh\A>? NGfMeZBFVVOR MojaTWM2OD1yLkC4JO69VQ>? NGDCWFkzPjV5NUG2Oy=>
HCCLM3 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mm\FNE0yOCEQvF2= NHvMSWQ2KGR? NWS5TIZPTE2VTx?= MW\JR|UxRTBwMUSg{txO MoXHNlY2PzVzNke=
HuH7 M{PTZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlfQNE0yOCEQvF2= NH:wS202KGR? MkO4SG1UVw>? M4W2eWlEPTB;MD6yNUDPxE1? MkTUNlY2PzVzNke=
HepG2 Mn3BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFzjToUxNTFyIN88US=> NY\yRXY1PSCm M3nQXGROW09? M3vzdWlEPTB;MD6zOEDPxE1? M37EVlI3PTd3MU[3
SMMC7721 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVXKbplHOC1zMDFOwG0> Mn;ROUBl Ml[xSG1UVw>? Ml\kTWM2OD1yLkSxJO69VQ>? M37XXVI3PTd3MU[3
BEL7402 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4rkfFAuOTBizszN MVm1JIQ> MoG5SG1UVw>? NIfpeHRKSzVyPUCuOFch|ryP M3W3OlI3PTd3MU[3
MHCC97H NEnTZ|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGK1WGUxNTFyIN88US=> NGT4OYQ2KGR? NFTM[JJFVVOR NH3uNJVKSzVyPUCuOFEh|ryP NYXVOHh6OjZ3N{WxOlc>
Hep3B MVLD[YxtKEO7Y3zlJGF{e2G7 NFPHfHgxNjFxMD61M|IvPSEQvF2= MUK0PEBp M4LodmROW09? M4fUeIxm[WS|IITvJIEhe3Wkc4ThcpRq[WxiYXPjeY12dGG2aX;uJI9nKEiFQzDj[YxteyCrbjDzeYIuTzFicHjhd4XDqA>? NV35dVk4OjZ3N{WxOlc>
HCCLM3 MVLD[YxtKEO7Y3zlJGF{e2G7 NVu5SHVkOC5zL{CuOU8zNjVizszN NXrM[HV1PDhiaB?= NUDXWnlrTE2VTx?= M1HiZoxm[WS|IITvJIEhe3Wkc4ThcpRq[WxiYXPjeY12dGG2aX;uJI9nKEiFQzDj[YxteyCrbjDzeYIuTzFicHjhd4XDqA>? MXGyOlU4PTF4Nx?=
Hep3B NFzzZYVCeG:ydH;zbZMhSXO|YYm= NFL2RXExNjFxMD61M|IvPSEQvF2= NF:1PHY1QCCq M1LRNWROW09? MYHhZ5RqfmG2ZYOgZ4F{eGG|ZT2zJIFv\CClYYPwZZNmNTliZYjwdoV{e2mxbjDhcoQhcW6mdXPl[EBRSVKSIHPs[YF3[WenIHHzJJdmdGxiYYOgZ5l1d2Oqcn;t[UBkKHKnbHXhd4UhcW62bzD0bIUh[3m2b4DsZZNuKG[{b32gcYl1d2Oqb37kdoli MoP1NlY2PzVzNke=
HCCLM3 MofnRZBweHSxc3nzJGF{e2G7 MVGwMlEwOC53L{KuOUDPxE1? M4jkXFQ5KGh? MmOwSG1UVw>? MoKzZYN1cX[jdHXzJINie3Cjc3WtN{BidmRiY3HzdIF{\S17IHX4dJJme3Orb36gZY5lKGmwZIXj[YQhWEGUUDDjcIVifmGpZTDhd{B4\WyuIHHzJIN6fG:laILvcYUh[yC{ZXzlZZNmKGmwdH:geIhmKGO7dH;wcIF{dSCocn;tJI1qfG:laH;u[JJq[Q>? Mn;WNlY2PzVzNke=
A549 NW\jSG5{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW[wMlEuOTBizszN M3mxZ|czKGh? MlyxbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NE\pXFkzPjRzNUKyOS=>
H157 NELYXJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGLiVVkxNjFvMUCg{txO MXu3NkBp MmL6bY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NV7oVm9ROjZ2MUWyNlU>
H1299 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1zGNVAvOS1zMDFOwG0> M1;oZVczKGh? NGHFdlRqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MYKyOlQyPTJ{NR?=
A549 MVPGeY5kfGmxbjDBd5NigQ>? NIX2RnQyNzJwNT:1JO69VQ>? NEHP[JMyOiCq M1LibeKhf2Wja3z5JIRm[3KnYYPl[EBD[2xvMjDs[ZZmdHN? NYXWTWJkOjZ2MUWyNlU>
H1299 NEPQO5BHfW6ldHnvckBCe3OjeR?= M2rMfVEwOi53L{Wg{txO MXqxNkBp MlPmxsB4\WGtbImg[IVkemWjc3XkJGJkdC1{IHzleoVtew>? MmqzNlY1OTV{MkW=
H157 M3nBe2Z2dmO2aX;uJGF{e2G7 NGrwUmgyNzJwNT:1JO69VQ>? M2jmVFEzKGh? NGHrTJJl\WO{ZXHz[YQhTFJ2IHX4dJJme3Orb36= M{HxTlI3PDF3MkK1
H1299 NEOwfVZHfW6ldHnvckBCe3OjeR?= M4PYRVEwOi53L{Wg{txO NYH5UXFVOTJiaB?= NISzToJl\WO{ZXHz[YQhTFJ2IHX4dJJme3Orb36= MnH3NlY1OTV{MkW=
C8161 M1[xRmNmdGxiVnnhZoltcXS7IFHzd4F6 NXPMe4ppOC1{IN88US=> NG\j[5E1KGR? M1zWcWROW09? NEWzTHRl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= NFHKRoIzPjN7N{KyNy=>
Mel285 NV;DfYF6S2WubDDWbYFjcWyrdImgRZN{[Xl? M{H2UlAuOiEQvF2= MnHOOEBl NVSze41nTE2VTx?= NUjX[FZE\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NVnJdlZQOjZ|OUeyNlM>
Mel290 M3vRNGNmdGxiVnnhZoltcXS7IFHzd4F6 NGjFPI0xNTJizszN NHqwd5o1KGR? MUHEUXNQ MYjk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NFvkR3YzPjN7N{KyNy=>
92.1 MUHD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NHjWe3cxNTJizszN NETQNXE1KGR? M37J[mROW09? NIT0XY5l\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= M1jBbFI3Ozl5MkKz
Omm1.3 MmjZR4VtdCCYaXHibYxqfHliQYPzZZk> M3XYOVAuOiEQvF2= M2nwTFQh\A>? MUDEUXNQ Mmfo[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ MUmyOlM6PzJ{Mx?=
Mel202 M1zy[2NmdGxiVnnhZoltcXS7IFHzd4F6 M13JUFAuOiEQvF2= MUK0JIQ> NYDtOHB1TE2VTx?= MVzk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MmLxNlY{QTd{MkO=
Mel270 NF7oWWhE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NWTpWXE3OC1{IN88US=> NHjkbVI1KGR? MkW4SG1UVw>? M3G3PYRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= M3L5eFI3Ozl5MkKz
Omm1 NHrDco1E\WyuIG\pZYJqdGm2eTDBd5NigQ>? MoDENE0zKM7:TR?= M1vSUFQh\A>? MWnEUXNQ NGH0SXJl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= NV7jWoE1OjZ|OUeyNlM>
92.1 MVLBdI9xfG:|aYOgRZN{[Xl? MWi1NFAhdk1? M2PCNFQ5KGh? M{LxT2ROW09? M4r0Zolv\HWlZYOgZZBweHSxc3nz M1PUSFI3Ozl5MkKz
Omm1.3 NFXTXXdCeG:ydH;zbZMhSXO|YYm= M4e2d|UxOCCwTR?= MUK0PEBp M1nxXmROW09? Mk\hbY5lfWOnczDhdI9xfG:|aYO= MUWyOlM6PzJ{Mx?=
92.1 M3\ldmNmdGxiQ4njcIUhSXO|YYm= MnTmOVAxKG6P MmqxNlQwPDhxN{KgbC=> M{jWbmROW09? M323UIlv\HWlZYOgeIhmKGOnbHygZYNkfW23bHH0bY9vKGG2IIP1Zk1IOcLi NWLN[|d6OjZ|OUeyNlM>
Omm1.3 NFjlR4xE\WyuIFP5Z4xmKEG|c3H5 NEPzZ3E2ODBibl2= NHnZTGozPC92OD:3NkBp MnyxSG1UVw>? MULpcoR2[2W|IITo[UBk\WyuIHHjZ5VufWyjdHnvckBifCC|dXKtS|HDqA>? NYjOb25VOjZ|OUeyNlM>
A549 NI\VS|BHfW6ldHnvckBCe3OjeR?= MWWxNFAwPDByL{GwNFAhdk1? M1;3PFI1KGh? M{T4UZVxemWpdXzheIV{KGGwZDDhZ5RqfmG2ZYOgV2lTXDF? NXvDUoNCOjZ{MUKxPVk>
MCF-7 MXXGeY5kfGmxbjDBd5NigQ>? M{f6WVExOC92MECvNVAxOCCwTR?= M{PCZ|I1KGh? M3XRSJVxemWpdXzheIV{KGGwZDDhZ5RqfmG2ZYOgV2lTXDF? Mly3NlYzOTJzOUm=
HEK293 MWTGeY5kfGmxbjDBd5NigQ>? NXvGVm5uOTByL{SwNE8yODByIH7N NIf2WoUzPCCq M{HadZVxemWpdXzheIV{KGGwZDDhZ5RqfmG2ZYOgV2lTXDF? MlTsNlYzOTJzOUm=
858 NUT2fXhwS2WubDDWbYFjcWyrdImgRZN{[Xl? M3XWS|AuOSEQvF2= MVe1JIQ> MmT6SG1UVw>? MoLR[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NFXVV|QzPjJyNkOzNy=>
DDR2L63V NVftXXJoS2WubDDWbYFjcWyrdImgRZN{[Xl? MWSwMVEh|ryP NUjZemhLPSCm Mo\ySG1UVw>? M1;aWIRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= M2fiVVI3OjB4M{Oz
BE(2)-C M4PaOGNmdGxiVnnhZoltcXS7IFHzd4F6 Mn31NUDPxE1? NF;qNIIyNTRiZB?= NEHMUWtl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgd4lodmmoaXPhcpRtgQ>? NETsdmkzPjB4N{S2OC=>
IMR-32 MXnD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NHLzZYgyKM7:TR?= M1G0V|EuPCCm Ml7U[IVkemWjc3XzJINmdGxidnnhZoltcXS7IIPp[45q\mmlYX70cJk> Ml63NlYxPjd2NkS=
JF NWDH[3FzS2WubDDWbYFjcWyrdImgRZN{[Xl? MVqxJO69VQ>? M1vB[lEuPCCm MXXk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHlic3nncolncWOjboTsfS=> MnixNlYxPjd2NkS=
BE(2)-M17 NEDV[3ZE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NGrSSnEyKM7:TR?= M{fhUlEuPCCm M3eyU4Rm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDzbYdvcW[rY3HueIx6 MnLqNlYxPjd2NkS=
SK-N-SH M4nhOGNmdGxiVnnhZoltcXS7IFHzd4F6 MX6xJO69VQ>? MYexMVQh\A>? M4fPXYRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDzbYdvcW[rY3HueIx6 M33FSFI3ODZ5NE[0
SK-N-DZ  MYfD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MY[xJO69VQ>? M3fORVEuPCCm MXrk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHlic3nncolncWOjboTsfS=> MkPONlYxPjd2NkS=
HMC-1.1  MlX0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYG1MVUxODBibl2= NEXGdYs1QCCq M2\S[WROW09? Mm\ZbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NHfZXFIzPjB3NUOwNy=>
HMC-1.2 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnTqOU02ODByIH7N NYnkT3ZGPDhiaB?= MUPEUXNQ M2LaOIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NYXYOo9MOjZyNUWzNFM>
ROSA KIT WT  NUOxcGxYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH7ndpE2NTVyMECgcm0> MVK0PEBp MmjFSG1UVw>? NVTQV3dMcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MnS3NlYxPTV|MEO=
ROSA KIT D816V M4DsRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXi1MVUxODBibl2= MUC0PEBp NWfMVINTTE2VTx?= NFTRTJJqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MlW0NlYxPTV|MEO=
HMC-1.1  Mn:3RZBweHSxc3nzJGF{e2G7 NYe4[VV7OjByLUWwNFAhdk1? Ml\SOFghcA>? MX3EUXNQ M{Dwfolv\HWlZYOgZ4VtdCCjcH;weI9{cXNiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NIPBVoczPjB3NUOwNy=>
HMC-1.2 M2XSNGFxd3C2b4Ppd{BCe3OjeR?= NXvwZW9ROjByLUWwNFAhdk1? M3XIOlQ5KGh? NW\ycXFrTE2VTx?= NXvEVVMycW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NFvDUnAzPjB3NUOwNy=>
ROSA KIT WT  MXnBdI9xfG:|aYOgRZN{[Xl? M3jWPVIxOC13MECwJI5O NHXHZmI1QCCq NIW2XFFFVVOR NFfvTW1qdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ MlvmNlYxPTV|MEO=
ROSA KIT D816V M4CwdmFxd3C2b4Ppd{BCe3OjeR?= Ml7QNlAxNTVyMECgcm0> NETRSYE1QCCq MVfEUXNQ MVnpcoR2[2W|IHPlcIwh[XCxcITvd4l{KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MUKyOlA2PTNyMx?=
494H MorYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEexNZk4OiCq MnvNSG1UVw>? NHK0NXdKSzVyPUCuNVIzyrFyLkCwOEDPxE1? NVHxdmY1OjV7NES1OlY>
493H NEPsclVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3K1UFczKGh? NU\mUlZSTE2VTx?= MonGTWM2OD1yLkC0O:KyOC5yMEmg{txO NYqzUYVJOjV7NES1OlY>
716H MnLSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW\4XGVJPzJiaB?= M2rMVmROW09? NF3NUGNKSzVyPUCuNlEzyrFyLkCzOEDPxE1? NWWyW3VmOjV7NES1OlY>
148I MnT3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmfQO|IhcA>? NGfmdXRFVVOR NVTwWVdmUUN3ME2wMlI5PMLzMD6wN|Uh|ryP MkjpNlU6PDR3Nk[=
98Sc Mor0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX:3NkBp M2LiVGROW09? NFPhNVFKSzVyPUCuNVE2yrFyLkCwOEDPxE1? NWq2fYFWOjV7NES1OlY>
89R MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV23NkBp NFTWRYtFVVOR NWDNSIJkUUN3ME2wMlEzPsLzMD6wNFMh|ryP MUSyOVk1PDV4Nh?=
494L NYi1cmtXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI\mdVA4OiCq MmeySG1UVw>? M3;ZVmlEPTB;MD6zNVfDuTBwMEGyJO69VQ>? MmHaNlU6PDR3Nk[=
493L MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXjIVG5JPzJiaB?= MXLEUXNQ M3\xW2lEPTB;MD6wOVDDuTBwMEGxJO69VQ>? NVzuUnNvOjV7NES1OlY>
148L Mm\WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHnrfHA4OiCq M3\tS2ROW09? NYDiT|VbUUN3ME2wMlE1PsLzMD6wNVch|ryP NHPsPWEzPTl2NEW2Oi=>
98L M4fUW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn3zO|IhcA>? M4Swd2ROW09? MoXjTWM2OD1yLkOwPeKyOC5yMkmg{txO M1v6ZlI2QTR2NU[2
OS17 M1rRSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVflTZp1PzJiaB?= MknkSG1UVw>? M1\S[mlEPTB;MD6wO|nDuTBwMECzJO69VQ>? NVPPNG1LOjV7NES1OlY>
OS9 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnyyO|IhcA>? M4\5cWROW09? NG[zSmRKSzVyPUCuOFA3yrFyLkCyPEDPxE1? NX\lOZpoOjV7NES1OlY>
MG63 M1\CVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH2yb|I4OiCq NEj2SHVFVVOR NH6zVJBKSzVyPUCuNVE1yrFyLkCyOUDPxE1? MUSyOVk1PDV4Nh?=
SAOS2 MmCwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHrIdYU4OiCq NF;Tc|VFVVOR NX36fYVXUUN3ME2wMlIyP8LzMD6wNFMh|ryP NVPQVJJOOjV7NES1OlY>
U2OS MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYL3SHJYPzJiaB?= M3HoeGROW09? MYnJR|UxRTBwMUm4xtExNjByODFOwG0> MknzNlU6PDR3Nk[=
SJSA-1 M1;mfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHT1NmY4OiCq M1fLcGROW09? NHy4V4JKSzVyPUCuNVAxyrFyLkCxNEDPxE1? MlPKNlU6PDR3Nk[=
494H MmrERZBweHSxc3nzJGF{e2G7 MXiwMlI2NzBwNT:xMlAh|ryP NI\abGQzPCCq M2L6VWROW09? MoXWbY5kemWjc3XzJIxmfmWuczDv[kBkdGWjdnXkJINie3Cjc3WtN:Kh M4mwOVI2QTR2NU[2
148I MlTDRZBweHSxc3nzJGF{e2G7 NWTNbVJCOC5{NT:wMlUwOS5yIN88US=> NFHW[I0zPCCq Ml6wSG1UVw>? MoK1bY5kemWjc3XzJIxmfmWuczDv[kBkdGWjdnXkJINie3Cjc3WtN:Kh NYfqc3JDOjV7NES1OlY>
OS17 MkW4RZBweHSxc3nzJGF{e2G7 M1i4NVAvOjVxMD61M|EvOCEQvF2= M4PaXlI1KGh? MULEUXNQ M{T5V4lv[3KnYYPld{Bt\X[nbIOgc4Yh[2ynYY\l[EBk[XOyYYPlMVPDqA>? NUC4bZd4OjV7NES1OlY>
494H MUfBdI9xfG:|aYOgRZN{[Xl? NXXHdGRUOeLCid88US=> MYS0PEBp M3Lwb2ROW09? M3H1Nolv\HWlZYOgZ4VtdCCjcH;weI9{cXNic3nncolncWOjboTsfS=> M2m0elI2QTR2NU[2
148I M1;yZ2Fxd3C2b4Ppd{BCe3OjeR?= M3TGTFHjiIoQvF2= M4LGRlQ5KGh? Mlj2SG1UVw>? M3m4U4lv\HWlZYOgZ4VtdCCjcH;weI9{cXNic3nncolncWOjboTsfS=> Ml21NlU6PDR3Nk[=
OS17 MU\BdI9xfG:|aYOgRZN{[Xl? MX2x5qCK|ryP NU\kNoRyPDhiaB?= NGHTTHBFVVOR NInpWIxqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IIPp[45q\mmlYX70cJk> NV;EUpFVOjV7NES1OlY>
MOLM13 NYfrT4NYSXCxcITvd4l{KEG|c3H5 MkjLNlUxKG6P NFKwWFM1QCCq NXfI[|JGTE2VTx?= NGrrcY9qdmS3Y3XzJJNq\26rZnnjZY51dHliYYDvdJRwe2m|IHPveJJm[XSvZX70JJdqfGhicYXpfoFzfGmwaXK= NY[0XYxHOjVyNUO4NlU>
MV4-11  MmLmRZBweHSxc3nzJGF{e2G7 MYKyOVAhdk1? MU[0PEBp NF;GR2NFVVOR MWLpcoR2[2W|IIPp[45q\mmlYX70cJkh[XCxcITvd4l{KGOxdILlZZRu\W62IIfpeIgheXWrenHyeIlvcWJ? MUiyOVA2Ozh{NR?=
MOLM13 NGXJcmpHfW6ldHnvckBCe3OjeR?= MlLZNlUxKG6P NVP2TnBKOjRiaB?= NUDJcG9yTE2VTx?= MmSy[Y5p[W6lZYOgdZVqgmG{dHnubYIucW6mdXPl[EBud3KnIICyNUwhSkmPLDDhcoQh[2ynYY\l[EBRSVKS NX7rRm1xOjVyNUO4NlU>
MV4-11  NXjle4l4TnWwY4Tpc44hSXO|YYm= NGjXNo0zPTBibl2= MkGwNlQhcA>? M3HHXGROW09? NIPUTlBmdmijbnPld{ByfWm8YYL0bY5q[i2rbnT1Z4VlKG2xcnWgdFIyNCCESV2sJIFv\CClbHXheoVlKFCDUmC= NGnRUVIzPTB3M{iyOS=>
MOLM13 MVTBdI9xfG:|aYOgRZN{[Xl? MUeyOVAhdk1? MV60PEBp MnW2SG1UVw>? NWj0TWlOcW6mdXPld{B{cWewaX\pZ4FvfGy7IHHwc5B1d3OrczDjc5Rz\WG2bXXueEB4cXSqIIDvcoF1cW6rYh?= MX2yOVA2Ozh{NR?=
MV4-11  MmHCRZBweHSxc3nzJGF{e2G7 MXWyOVAhdk1? MlzXOFghcA>? NIDOU3lFVVOR M2m3RYlv\HWlZYOgd4lodmmoaXPhcpRtgSCjcH;weI9{cXNiY3;0doVifG2nboSge4l1cCCyb37heIlvcWJ? NHXFe40zPTB3M{iyOS=>
Hela MV\D[YxtKF[rYXLpcIl1gSCDc4PhfS=> NXfuXWJlOC13MECgcm0> MnW1O|IhcA>? M3TsWGROW09? NWCy[pRl\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy MVqyOVAxQTJ7NR?=
HBL-1 M2DtWmNmdGxiVnnhZoltcXS7IFHzd4F6 M172OFAuPTByIH7N MWS3NkBp M3m4[mROW09? MnXW[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ MVmyOVAxQTJ7NR?=
HLY-1 M37CSGNmdGxiVnnhZoltcXS7IFHzd4F6 M1;2[lAuPTByIH7N NUnUZmtVPzJiaB?= M2\icGROW09? MmXY[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ MVeyOVAxQTJ7NR?=
OCI-Ly3 NHTvTZBE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NWKxRopzOC13MECgcm0> NUPlfWNXPzJiaB?= MWXEUXNQ Ml7q[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NYLhRmV6OjVyMEmyPVU>
OCI-Ly10 M4rqeWNmdGxiVnnhZoltcXS7IFHzd4F6 MWiwMVUxOCCwTR?= MmX6O|IhcA>? NWPGc3FCTE2VTx?= MoH2[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ MknQNlUxODl{OUW=
SU-DHL-4 NID0TIJE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NILsPWIxNTVyMDDuUS=> MVq3NkBp MXHEUXNQ NUnPNoNx\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NFHn[lkzPTByOUK5OS=>
SU-DHL-5 Ml3aR4VtdCCYaXHibYxqfHliQYPzZZk> NVexe2h3OC13MECgcm0> M3TEfFczKGh? Mkn5SG1UVw>? NI\0bFJl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= NIfJWWwzPTByOUK5OS=>
SU-DHL-6 M1jVS2NmdGxiVnnhZoltcXS7IFHzd4F6 NY[yV2J1OC13MECgcm0> NEnJbZM4OiCq MX\EUXNQ M1\Kc4Rm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= MUOyOVAxQTJ7NR?=
SU-DHL-10 Mn7uR4VtdCCYaXHibYxqfHliQYPzZZk> NVvxVFBxOC13MECgcm0> NFnPZoE4OiCq NVn1[|N5TE2VTx?= MV\k[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MnfZNlUxODl{OUW=
RC-K8 MVPD[YxtKF[rYXLpcIl1gSCDc4PhfS=> M4fiNVAuPTByIH7N MkTIO|IhcA>? NWLLT2NoTE2VTx?= Mnz1[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ MYKyOVAxQTJ7NR?=
OCI-Ly8 NXH4V|lPS2WubDDWbYFjcWyrdImgRZN{[Xl? NEPyU|UxNTVyMDDuUS=> NHrQfmw4OiCq M{nwNmROW09? Mnfl[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NYjHbVUzOjVyMEmyPVU>
OCL-Ly18 MVPD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NWflV4I4OC13MECgcm0> NFPTdoc4OiCq Mo\ESG1UVw>? MWDk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MnvmNlUxODl{OUW=
OCI-Ly3 M3PNZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mnr1NVczNzJ3MD:1NFAhdk1? NET3TYczNzdiZB?= M{\ndmROW09? MoewbY5lfWOnczDj[YxtNWO7Y3zlJIFzemW|dDDheEB{fWJvR{Gge4l1cCCvaX7pcYFtKGOnbHyg[IVifGkEoB?= Mmf5NlUxODl{OUW=
OCI-Ly8 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV\VZmlYOTd{L{K1NE82ODBibl2= MVuyM|ch\A>? M3ziNmROW09? NILMcpFqdmS3Y3XzJINmdGxvY4njcIUh[XK{ZYP0JIF1KHO3Yj3HNUB4cXSqIH3pcolu[WxiY3XscEBl\WG2aNMg NYS5ZpllOjVyMEmyPVU>
SU-DHL-4 MnjCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkfWNVczNzJ3MD:1NFAhdk1? MW[yM|ch\A>? MoLiSG1UVw>? NVntXIZNcW6mdXPld{Bk\WyuLXP5Z4xmKGG{cnXzeEBifCC|dXKtS|Ehf2m2aDDtbY5qdWGuIHPlcIwh\GWjdHlCpC=> NV\m[I5wOjVyMEmyPVU>
SU-DHL-10 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHHqPWoyPzJxMkWwM|UxOCCwTR?= MmXtNk84KGR? MX3EUXNQ MmP3bY5lfWOnczDj[YxtNWO7Y3zlJIFzemW|dDDheEB{fWJvR{Gge4l1cCCvaX7pcYFtKGOnbHyg[IVifGkEoB?= NEi5SZkzPTByOUK5OS=>
OCI-Ly3 MkfyRZBweHSxc3nzJGF{e2G7 MofCNVczNzJ3MDDuUS=> NXLnO5hkP2R? M1XCZmROW09? MWfpcoNz\WG|ZYOgZ4F{eGG|ZT2zM|ch[WO2aY\peJnDqHOrZ37p[olk[W62bIm= NE\GfI4zPTByOUK5OS=>
OCI-Ly8 MVXBdI9xfG:|aYOgRZN{[Xl? Mlq3NVczNzJ3MDDuUS=> MWm3[C=> MkLYSG1UVw>? MoDEbY5kemWjc3XzJINie3Cjc3WtN{84KGGldHn2bZR6yqC|aXfubYZq[2GwdHz5 NYPDcnF7OjVyMEmyPVU>
SU-DHL-4 MkX5RZBweHSxc3nzJGF{e2G7 MnTnNVczNzJ3MDDuUS=> NXruOHN{P2R? M4PGVmROW09? M3n5OYlv[3KnYYPld{Bk[XOyYYPlMVMwPyCjY4Tpeol1gcLic3nncolncWOjboTsfS=> NEXkUmszPTByOUK5OS=>
SU-DHL-10 NHXyNWdCeG:ydH;zbZMhSXO|YYm= MmHrNVczNzJ3MDDuUS=> NWq0VJJJP2R? NH;kZlZFVVOR MlH0bY5kemWjc3XzJINie3Cjc3WtN{84KGGldHn2bZR6yqC|aXfubYZq[2GwdHz5 NUPOVnA4OjVyMEmyPVU>

... Click to View More Cell Line Experimental Data

In vivo (+)-JQ1 (50 mg/kg) inhibits tumors growth in mice with NMC 797 xenografts. (+)-JQ1 (50 mg/kg) results in effacement of NUT nuclear speckles in mice with NMC 797 xenografts, consistent with competitive binding to nuclear chromatin. (+)-JQ1 (50 mg/kg) induces strong (grade 31) keratin expression in NMC 797 xenografts. (+)-JQ1 (50 mg/kg) promotes differentiation, tumor regression and prolonged survival in mice models of NMC xenografts. [1] (+)-JQ1 (50 mg/kg) results in a significant prolongation in overall survival of SCID-beige mice orthotopically xenografted after intravenous injection with MM.1S-luc+ cells compared to vehicle-treated animals. [2] (+)-JQ1 (50 mg/kg i.p.) leads to a highly significant increase in survival of mice bearing Raji xenografts. [3]

Protocol

Cell Research:

[1]

+ Expand
  • Cell lines: MC 11060 cells
  • Concentrations: ~500 nM
  • Incubation Time: 48 hours
  • Method:

    Cells are seeded into white, 384-well microtiter plates at 500 cells per well in a total volume of 50 μL media. The 797, TT and TE10 cells are grown in DMEM containing 1% penicillin/streptomycin and 10% FBS. The Per403 cells are grown in DMEM containing 1 % penicillin/streptomycin and 20% FBS. Patient-derived NMC 11060 cells are grown in RPMI with 10% FBS and 1% penicillin/streptomycin. (+)-JQ1 is delivered to microtiter assay plates by robotic pin transfer. Following a 48 hours incubation at 37℃, cells are lysed and wells are assessed for total ATP content using a commercial proliferation assay. Replicate measurements are analyzed with respect to dose and estimates of IC50 are calculated by logistic regression (GraphPad Prism).


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: Mice bearing NMC 797 xenografts
  • Formulation: 5% DMSO in 5% dextrose
  • Dosages: 50 mg/kg
  • Administration: intraperitoneal injection
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 91 mg/mL (199.12 mM) warming
Ethanol 91 mg/mL (199.12 mM)
Water <1 mg/mL
In vivo 2% DMSO+30% PEG 300+5% Tween 80+ddH2O 5mg/mL

* 1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 456.99
Formula

C23H25ClN4O2S

CAS No. 1268524-70-4
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Epigenetic Reader Domain Signaling Pathway Map

Epigenetic Reader Domain Inhibitors with Unique Features

Tags: buy (+)-JQ1 | (+)-JQ1 supplier | purchase (+)-JQ1 | (+)-JQ1 cost | (+)-JQ1 manufacturer | order (+)-JQ1 | (+)-JQ1 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID